PRISCOLINE
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Mar 1948
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PRISCOLINE is a small-molecule injectable approved in 1948 by Novartis. The specific indication and mechanism of action are not currently documented in available data. This is a legacy product nearing loss of exclusivity.
LOE Approaching
This legacy injectable faces moderate competitive pressure (30%) and approaching loss of exclusivity, suggesting a declining product with minimal team expansion opportunity.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings and approaching LOE status indicate minimal career development opportunity. Working on PRISCOLINE would primarily involve defending market share and managing decline rather than growth execution.
Brand ManagerProduct Manager
Worked on PRISCOLINE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.